For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Stoke Therapeutics Inc (NASDAQ: STOK) closed at $19.56 in the last session, down -0.61% from day before closing price of $19.68. In other words, the price has decreased by -$0.61 from its previous closing price. On the day, 1.15 million shares were traded. STOK stock price reached its highest trading level at $19.91 during the session, while it also had its lowest trading level at $19.1324.
Ratios:
We take a closer look at STOK’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.53. For the most recent quarter (mrq), Quick Ratio is recorded 6.98 and its Current Ratio is at 6.98. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on July 18, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On December 20, 2024, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $24.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 18 ’25 when Ticho Barry sold 2,805 shares for $18.24 per share. The transaction valued at 51,158 led to the insider holds 23,970 shares of the business.
Kaye Edward M. MD sold 12,126 shares of STOK for $221,154 on Aug 18 ’25. The Director now owns 153,470 shares after completing the transaction at $18.24 per share. On Aug 18 ’25, another insider, Allan Jonathan, who serves as the GENERAL COUNSEL & CORP SEC of the company, sold 1,683 shares for $18.24 each. As a result, the insider received 30,695 and left with 23,948 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, STOK now has a Market Capitalization of 1071837120 and an Enterprise Value of 827680512. As of this moment, Stoke’s Price-to-Earnings (P/E) ratio for their current fiscal year is 23.15. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.36 while its Price-to-Book (P/B) ratio in mrq is 3.20. Its current Enterprise Value per Revenue stands at 4.141 whereas that against EBITDA is 19.58.
Stock Price History:
The Beta on a monthly basis for STOK is 1.08, which has changed by 0.37940764 over the last 52 weeks, in comparison to a change of 0.1513431 over the same period for the S&P500. Over the past 52 weeks, STOK has reached a high of $19.70, while it has fallen to a 52-week low of $5.35. The 50-Day Moving Average of the stock is 46.84%, while the 200-Day Moving Average is calculated to be 80.66%.
Shares Statistics:
According to the various share statistics, STOK traded on average about 720.74K shares per day over the past 3-months and 1250260 shares per day over the past 10 days. A total of 54.72M shares are outstanding, with a floating share count of 45.92M. Insiders hold about 16.24% of the company’s shares, while institutions hold 108.25% stake in the company. Shares short for STOK as of 1753920000 were 11430622 with a Short Ratio of 15.86, compared to 1751241600 on 11534286. Therefore, it implies a Short% of Shares Outstanding of 11430622 and a Short% of Float of 25.330000000000002.
Earnings Estimates
The current rating of Stoke Therapeutics Inc (STOK) is the result of assessments by 9.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.54 and low estimates of -$0.81.
Analysts are recommending an EPS of between $0.48 and -$0.1 for the fiscal current year, implying an average EPS of $0.26. EPS for the following year is -$2.92, with 9.0 analysts recommending between -$2.3 and -$3.65.
Revenue Estimates
According to 10 analysts, the current quarter’s revenue is expected to be $6.06M. It ranges from a high estimate of $12M to a low estimate of $3M. As of the current estimate, Stoke Therapeutics Inc’s year-ago sales were $4.89MFor the next quarter, 10 analysts are estimating revenue of $5.47M. There is a high estimate of $11M for the next quarter, whereas the lowest estimate is $3M.
A total of 11 analysts have provided revenue estimates for STOK’s current fiscal year. The highest revenue estimate was $205.8M, while the lowest revenue estimate was $178.39M, resulting in an average revenue estimate of $185.57M. In the same quarter a year ago, actual revenue was $36.55M
